Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory concentration [IC 50] of 7.5 ± 0.3 nM) and HIV-1 integration in cells. BIC exhibits potent and selective in vitro antiretroviral activity in both T-cell lines and primary human T lymphocytes, with 50% effective concentrations ranging from 1.5 to 2.4 nM and selectivity indices up to 8,700 relative to cytotoxicity. BIC exhibits synergistic in vitro antiviral effects in pairwise combinations with tenofovir alafenamide, emtricitabine, or darunavir and maintains potent antiviral activity against HIV-1 variants resistant to other classes of antiretrovirals. BIC displayed an in vitro resistance profile that was markedly improved compared to the integrase strand transfer inhibitors (INSTIs) raltegravir (RAL) and elvitegravir (EVG), and comparable to that of dolutegravir (DTG), against nine INSTI-resistant site-directed HIV-1 mutants. BIC displayed statistically improved antiviral activity relative to EVG, RAL, and DTG against a panel of 47 patient-derived HIV-1 isolates with high-level INSTI resistance; 13 of 47 tested isolates exhibited >2-fold lower resistance to BIC than DTG. In dose-escalation experiments conducted in vitro, BIC and DTG exhibited higher barriers to resistance than EVG, selecting for HIV-1 variants with reduced phenotypic susceptibility at days 71, 87, and 20, respectively. A recombinant virus with the BIC-selected M50I/R263K dual mutations in IN exhibited only 2.8-fold reduced susceptibility to BIC compared to wild-type virus. All BIC-selected variants exhibited low to intermediate levels of cross-resistance to RAL, DTG, and EVG (<8-fold) but remained susceptible to other classes of antiretrovirals. A high barrier to in vitro resistance emergence for both BIC and DTG was also observed in viral breakthrough studies in the presence of constant clinically relevant drug concentrations. The overall virologic profile of BIC supports its ongoing clinical investigation in combination with other antiretroviral agents for both treatment-naive and -experienced HIV-infected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the last 14 years, four more INSTIs were approved for treatment of HIV infection: elvitegravir, dolutegravir, bictegravir and cabotegravir147–150.”
From Structure and function of retroviral integrase (2022) · cites this paper as [149]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
A quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S. T., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 687
A three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544
Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., Richmond, G., Buendia, C. B., Fourie, J., Ramgopal, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61221-0 · Cited by 516
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708978 · Cited by 509
Clotet, B., Feinberg, J., van Lunzen, J., Khuong-Josses, M.-A., Antinori, A., Dumitru, I., Pokrovskiy, V., Fehr, J., Ortiz, R., Saag, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60084-2 · Cited by 507
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., Foster, S. A., Hazen, R. J., Miki, S., Suyama-Kagitani, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01209-10 · Cited by 382
Raffi, F., Jaeger, H., Quiros-Roldan, E., Albrecht, H., Belonosova, E., Gatell, J. M., Baril, J.-G., Domingo, P., Brennan, C., Almond, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70257-3 · Cited by 379
Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01534-07 · Cited by 343
Research works printed but not linked: 7
- Lepik KJ, Yip B, Robbins M, Woods C, Lima VD, McGovern RA, Zhang WW, Barrios R, Montaner JSG, Harrigan PR. 2016. Prevalence and incidence of integrase drug resistance in BC, Canada 2009-2015. Abstr 23rd Conf Retroviruses Opportunistic Infect, abstr 492LB.
- ViiV Healthcare. 2015. Tivicay 50 mg film-coated tablets. ViiV Healthcare, Middlesex, United Kingdom.
- Lazerwith SE, Cai R, Chen X, Desai MC, Eng S, Jacques R, Ji M, Martin H, McMahon C, Mish M, Morganelli P, Mwangi J, Pyun HJ, Schmitz U, Stepan G, Szwarcberg J, Tang J, Tsiang M, Wang J, White K, Wiser L, Zack J, Jin H. 2016. Discovery of bictegravir (GS-9883), a novel, unboosted, once-daily HIV-1 integrase strand transfer inhibitor (INSTI) with improved pharmacokinetics and in vitro resistance profile. ASM Microbe 2016, poster 414.
- Pozniak A, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Hagins D, Buendia CB, Dorey D, Griffith S, Min S. Dolutegravir (DTG) versus raltegravir (RAL) in ART-experienced, integrase-naive subjects: 24 week interim results from SAILING (ING111762). Abstr 20th Conf Retroviruses Opportunistic Infect, abstr 179LB.
- Jones G, Ledford RM, Yu F, Chen X, Miller MD, Tsiang M, McColl DJ. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). Abstr 14th Conf Retroviruses Opportunistic Infect, abstr 627.
- Abram M, Margot N, Barnes T, Ram R, Chen X, White K, Miller M, Callebaut C. 2014. Clinical impact and characterization of HIV integrase inhibitor resistance associated with T97A: a low-level polymorphic integrase mutation, abstr POH-017. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
- 10.1310/hct1504-218 · DOI
Cited by
Items 201–300 of 331
Sayan, M., Yildirim, F. S., Akhan, S., Karaoglan, I., & Akalin, H. (2022) · Current HIV Research · doi:10.2174/1570162x20666220303104509 · Cited by 7
Armenia, D., Marchegiani, G., Spalletta, D., Carioti, L., Tavelli, A., Bellocchi, M. C., Spagnuolo, V., Mazzotta, V., Quirós-Roldán, E., Bono, V., et al. (2025) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2025.04.002 · Cited by 7
Potential inhibitor for 2019-novel coronaviruses in drug development
Qiu, G., Xu, X., Dang, Z., Zhang, L., Zhuang, L., Jing, W., & Ji, L. (2020) · Cancer translational medicine · doi:10.4103/ctm.ctm_3_20 · Cited by 7
How frequent is dolutegravir resistance?
van Osch, J. A. T., & Mésplède, T. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2529431 · Cited by 7
Sidman, E. F., & Ondrush, N. M. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac339 · Cited by 7
Canetti, D., Galli, L., Lolatto, R., Nozza, S., Spagnuolo, V., Muccini, C., Trentacapilli, B., Bruzzesi, E., Ranzenigo, M., Chiurlo, M., et al. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s437043 · Cited by 7
Subramanian, R., Ling, J. R., Wang, J., Wang, K., Hao, J., Jin, H., Lai, Y., Murray, B. P., Wijaya, S., Zhang, H., et al. (2022) · Xenobiotica · doi:10.1080/00498254.2022.2159569 · Cited by 7
Self-citationKalemera, M. D., Maher, A. K., Dominguez‐Villar, M., & Maertens, G. N. (2024) · Pharmaceuticals · doi:10.3390/ph17060730 · Cited by 7
Rogg, L. E., Underwood, M., Hanan, N., Castillo‐Mancilla, J., Kahl, L. P., Halliday, F. C., Ghita, G. L., Jeffrey, J., Byrne, S., Onodera, T., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf135 · Cited by 6
Haaland, R. E., Fountain, J. J., Martin, A. M., Dinh, C. T., Holder, A. N., Edwards, T. E., Lupo, L. D., Hall, L., Conway-Washington, C., Massud, I., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac419 · Cited by 6
Adult Human Brain Tissue Cultures to Study NeuroHIV
Duyne, R. V., Irollo, E., Lin, A. M., Johnson, J. A., Guillem, A. M., O’Brien, E. V., Merja, L., Nash, B., Jackson, J. G., Sarkar, A., et al. (2024) · Cells · doi:10.3390/cells13131127 · Cited by 6
Ivashchenko, A. A., Ivanenkov, Y. A., Koryakova, A. G., Karapetian, R. N., Mitkin, O. D., Aladinskiy, V., Kravchenko, D. V., Savchuk, N., & Ivashchenko, A. V. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112064 · Cited by 6
Population pharmacokinetics of bictegravir in real-world people with HIV
Ekobena, P., Briki, M., Dao, K., Marzolini, C., Andre, P., Buclin, T., Cavassini, M. L., Guidi, M., Thoueille, P., Study, S. H. C., et al. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf297 · Cited by 6
Nuli, M. V., Jaini, P. K., Jami, D. G., Tummala, S. R., Chukka, A. K., & Tatapudi, H. K. (2025) · Separation Science Plus · doi:10.1002/sscp.70085 · Cited by 6
Chan, W., & Ly, W. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02411 · Cited by 6
Aghokeng, A. F., Ngo‐Giang‐Huong, N., Thu, H. H. K., Dagnra, A. Y., Toni, T. D., Maïga, A. I., Kania, D., Eymard‐Duvernay, S., Chaix, M., Cálvez, V., et al. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae087 · Cited by 6
Resistance to Dolutegravir—A Chink in the Armor?
Kuritzkes, D. R. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy186 · Cited by 6
Akiyama, T., Johns, B. A., Taoda, Y., Yoshida, H., Taishi, T., Kawasuji, T., Murai, H., Yoshinaga, T., Sato, A., Seki, T., et al. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129902 · Cited by 5
Binding assays enable discovery of Tet(X) inhibitors that combat tetracycline destructase resistance
Beech, M. J., Toma, E. C., Smith, H. G., Trush, M. M., Ang, J. H. J., Wong, M. Y., Wong, C. K., Ali, H. S., Butt, Z., Goel, V., et al. (2025) · Chemical Science · doi:10.1039/d5sc00964b · Cited by 5
Hocqueloux, L., Bonnet, F., Duvivier, C., Vassallo, M., Tollinchi, F., Leclercq, P., Karmochkine, M., Cordel, H., Deschanvres, C., Gordon, A. C., et al. (2025) · IJID Regions · doi:10.1016/j.ijregi.2025.100685 · Cited by 5
Pennetzdorfer, N., Naik, V., Montezuma-Rusca, J. M., Sklar, P. A., Callebaut, C., & Margot, N. (2026) · AIDS · doi:10.1097/qad.0000000000004495 · Cited by 5
An ultra-long-acting dimeric bictegravir prodrug defined by a short pharmacokinetic tail
Nayan, M. U., Sillman, B., Das, S., Hanson, B. W., Sultana, A., Le, N. T. H., Deodhar, S., Gowda, B., Dash, P. K., Agrawal, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68501-5 · Cited by 4
Demirdjian, S., Duong, V. N., Byrum, J. N., Nayak, A., McKinney, C. B., Perry, J. K., Callebaut, C., Rodgers, K. K., Falkard, B., & Feng, J. Y. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.02468-24 · Cited by 4
Mielczak, K., Serwin, K., Urbańska, A., Aksak‐Wąs, B., Karasińska‐Cieślak, M., Mularska, E., Witor, A., Jakubowski, P., Hlebowicz, M., Bociąga‐Jasik, M., et al. (2024) · Viruses · doi:10.3390/v16101597 · Cited by 4
Varriano, B. M., Sandler, I., Loutfy, M. R., Steinberg, S., Smith, G. H. R., Kovacs, C. M., Brunetta, J., Fletcher, D., Knox, D. C., Merkley, B., et al. (2019) · International Journal of STD & AIDS · doi:10.1177/0956462418815292 · Cited by 4
Wu, Y., Chmiel, A. F., & Bronson, J. J. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03492 · Cited by 4
Authentic HIV-1 integrase inhibitors for the treatment of HIV-1/AIDS
Liao, C., & Wang, Q. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18611-0.00026-7 · Cited by 4
Drug discovery and development: An overview of modern methods and principles
Blass, B. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817214-8.00001-4 · Cited by 4
Harris, E. L., Casas, C. P., Barnhart, M., Lin, A. H., Ferris, D., Ajose, O., Burgess, E. K., & Fowler, R. C. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000383 · Cited by 4
Taoda, Y., Akiyama, T., Tomita, K., Fujiwara-Kitamura, M., Tamura, Y., Kawasuji, T., Matsuoka, E., Akihisa, E., Seki, T., & Yoshinaga, T. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128664 · Cited by 4
Development of Synthetic Approaches Towards HIV Integrase Strand Transfer Inhibitors (INSTIs)
Sawant, A. A., Jadav, S. S., Nayani, K., & Mainkar, P. S. (2022) · ChemistrySelect · doi:10.1002/slct.202201915 · Cited by 4
Tırıs, G., Genc, A. A., Öven, E. N., & Erk, N. (2023) · Biomedical Chromatography · doi:10.1002/bmc.5712 · Cited by 4
D’Antoni, M. L., Falkard, B., Andreatta, K. N., Cox, S., Cohen, C. J., & Callebaut, C. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf019 · Cited by 4
Brar, I., Ruane, P. J., Berhe, M., Brinson, C. C., Benson, P. M., Henry, K., Liu, H., Andreatta, K. N., Hindman, J. T., & Ramgopal, M. N. (2025) · Medicine · doi:10.1097/md.0000000000041482 · Cited by 4
Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment
Bruzzesi, E., Muccini, C., & Castagna, A. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2428820 · Cited by 4
Singh, G. V. S., & Divakar, T. E. (2019) · Asian Journal of Organic & Medicinal Chemistry · doi:10.14233/ajomc.2019.ajomc-p163 · Cited by 4
Kaginkar, S., Remling‐Mulder, L., Sahoo, A., Pandey, T., Gurav, P., Sutar, J., Singh, A. K., Barnett, E., Panickan, S., Akkina, R., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1552563 · Cited by 4
Otto, A. O., & Fulco, P. P. (2021) · International Journal of STD & AIDS · doi:10.1177/09564624211011902 · Cited by 4
Peng, X., Xu, Y., Huang, Y., & Zhu, B. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s323762 · Cited by 4
Jaryal, R., & Khan, S. A. (2023) · BioMetals · doi:10.1007/s10534-023-00498-6 · Cited by 3
Zhao, X. Z., Li, M., Smith, S. J., Karbasi, A. B., Choudhuri, I., Jing, T., Lyumkis, D., Craigie, R., & Burke, T. R. (2025) · NAR Molecular Medicine · doi:10.1093/narmme/ugaf039 · Cited by 3
Orientaciones para el uso de terapia antirretroviral en personas que viven con VIH en Chile
María Elena Ceballos, V., Ortiz, F. B., Pablo Herrera, M., Carlos Perez, C., Rodrigo Vélez, B., Alejandro Afani, S., Ximena Araya, A., Cecilia Piñera, M., & Silva, M. A. (2024) · Revista chilena de infectología · doi:10.4067/s0716-10182024000600162 · Cited by 3
Zhang, L., Chen, L., Tang, J., Liu, X., Zheng, L., Wang, F., Huang, X., Cao, W., & Li, T. (2026) · HIV Medicine · doi:10.1111/hiv.70205 · Cited by 3
Andreatta, K. N., Willkom, M., Martin, R., Chang, S. D., Wei, L., Liu, H., Liu, Y.-P., Graham, H., Quirk, E. K., Martin, H., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz412 · Cited by 3
Self-citationDesarrollo de darunavir en todo el espectro de la infección por el VIH
Llibre, J. M. (2018) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(18)30391-4 · Cited by 3
Boschloo, W., & van Welzen, B. J. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-00982-7 · Cited by 3
Pierone, G., Brunet, L., Fusco, J. S., Sension, M., Dunbar, M. S., Gruber, J., Dieterich, D. T., & Fusco, G. (2025) · HIV Medicine · doi:10.1111/hiv.70105 · Cited by 3
Madhavi, A., Srinivas, M., & Gupta, N. K. (2024) · Journal of Young Pharmacists · doi:10.5530/jyp.2024.16.94 · Cited by 3
Temporal Evolution of Drug Resistance to HIV Integrase Inhibitors
Choudhuri, I., Olvera, J. G., Biswas, A., Haldane, A., Levy, R. M., & Lyumkis, D. (2026) · Viruses · doi:10.3390/v18050540 · Cited by 2
Extended-Release Pre-exposure Prophylaxis and Drug-Resistant HIV
Ma, Y., Kang, Y., Davenport, A. A., Aduamah, J. M., Link, K. G., & Gurski, K. F. (2024) · The IMA volumes in mathematics and its applications · doi:10.1007/978-3-031-58516-6_2 · Cited by 2
Lunkuse, S., Kiiza, R., Ssekagiri, A., Nannyonjo, M., Ntenkaire, N., Nassolo, F., Namagembe, H. S., Kiberu, F., Kabuuka, D., Andia, I., et al. (2025) · Viruses · doi:10.3390/v17121596 · Cited by 2
Synthesis of Hexahydroquinoline-3-carboxamide Derivatives and Their HIV-1 Antiviral Activity
Bode, M. L., Coyanis, E. M., Mohlala, R. L., & Fish, M. Q. (2022) · Heterocycles · doi:10.3987/com-21-14602 · Cited by 2
Soudeyns, H., & Dumond, J. B. (2020) · AIDS · doi:10.1097/qad.0000000000002634 · Cited by 2
Integrase inhibitors go head-to-head
Barber, T. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30017-6 · Cited by 2
Boopathy, A. V., D'Antoni, M. L., Andreatta, K., Chang, S., Hindman, J. T., & Callebaut, C. (2025) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003742 · Cited by 1
Rodríguez-López, E. R., López, P. L., Rodríguez, Y., Sánchez, R., Acevedo, V.-S., Encarnación-Medina, J., Tirado, G., Ortíz, C., Mésplède, T., & Rivera‐Amill, V. (2024) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2023.0128 · Cited by 1
Anti-HIV-1 Activity of the Integrase Strand Transfer Inhibitor ACC017
Ma, M.-D., Luo, R.-H., Li, C.-Y., Huang, G.-C., Long, X., He, F.-Y., Yang, L.-M., Fu, H.-L., & Zheng, Y. (2025) · Viruses · doi:10.3390/v18010033 · Cited by 1
Vivanco-Lira, A., & Nieto-Saucedo, J.-R. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2102.03876 · Cited by 1
Saccoliti, F., Patacchini, E., Cara, E., Zarbo, L., Messore, A., Albano, A., Ruggieri, G., Madia, V. N., Scipione, L., Costi, R., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.70428 · Cited by 1
New Antiretroviral Agents for HIV Infection
Fong, I. W. (2023) · Emerging infectious diseases of the 21st century · doi:10.1007/978-3-031-26078-0_12 · Cited by 1
Shahid, A., Zhang, W. W., Montoya, V., Cheung, P. K., Oliveira, N., Sidhu, M. S., Woods, C. K., Robbins, M., Brumme, C. J., & Harrigan, P. R. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/621755 · Cited by 1
Targeting HIV-1 integrase: A review of options, challenges and future directions
Bourquin, R. A., & Schaeffer, P. M. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153092 · Cited by 1
Pre-Exposure Prophylaxis (PrEP)-Associated HIV Monitoring and Self-Testing
Zhu, Y., & Sell, J. K. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf155 · Cited by 1
Darazi, P. E. (2021) · theses.fr (ABES) · doi:10.70675/7bb07492ze915z4ca3z845fzba3bb62a3520 · Cited by 1
Human immunodeficiency virus/acquired immunodeficiency syndrome in the infant
Shetty, A. K., & Maldonado, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-79525-8.00032-9 · Cited by 1
Dong, B. J. (2018) · Pharmacy Today · doi:10.1016/j.ptdy.2018.09.032 · Cited by 1
Rao, A. M., Fayaz, S. M., Divyashree, M. S., Gayam, P. K. R., Rahangdale, R. R., Patil, S., & Hariharapura, R. C. (2025) · Journal of Experimental Pharmacology · doi:10.2147/jep.s524226 · Cited by 1
DeArmond, P. D., & Bunch, D. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18649-3.00013-6 · Cited by 1
Sulashvili, N., Yaduvanshi, U., Yaduvanshi, N., Yadav, M., Abzianidze, E., Chichoyan, N., Gabunia, L., Gorgaslidze, N., Alavidze, N., Abuladze, N. B., et al. (2025) · GEORGIAN SCIENTISTS · doi:10.52340/gs.2025.07.03.30 · Cited by 1
Development of an HIV‐1 integrase genotyping assay for HIV‐1 subtype AE
Liu, Y., Margot, N., Kitrinos, K. M., & Callebaut, C. (2018) · Journal of Medical Virology · doi:10.1002/jmv.25376 · Cited by 1
Saladini, F., Giannini, A., Giammarino, F., Antonova, A. A., Ozhmegova, E., Kaiser, R., Dragoni, F., Boccuto, A., Vicenti, I., Sönnerborg, A. B., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag230 · Cited by 1
Oliveira, D., Cruz, D., Levin, L. P. K., Li, L., Norton, C. A., Dobek, G. L., Wang, X., Veazey, R. S., Watkins, M., Schauer, A. P., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050522 · Cited by 1
Siddika, A. (2025) · BRAC University Institutional Repository (BRAC University) · Cited by 1
HIV-1 Integrase During the Time: History of Drugs and Effort for the New Inhibitors’ Identification
Esposito, F., Saccoliti, F., Patacchini, E., & Santo, R. D. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_180
Protein‐Protein Interaction as an Efficient Target to Inhibit HIV‐1 Integrase
Zarghi, A., & Hajimahdi, Z. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70221
Pharmaceutical applications of organofluorine compounds
Reddy, V. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813286-9.00005-5
Carta, F., & Sechi, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823974-2.00006-1
BindingDB Entry 50018529: Advances in the development of HIV integrase strand transfer inhibitors.
BindingDB (2024) · UC San Diego · doi:10.7270/q25143gj
BindingDB Entry 50022399: Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023.
BindingDB (2025) · UC San Diego · doi:10.7270/q23201k8
HIV-1 integrase strand transfer inhibitor resistance to dolutegravir, bictegravir and cabotegravir
Zhang, W. W. (2023) · cIRcle (University of British Columbia) · doi:10.14288/1.0422972
Shahari, M. S. B., Offei, S., Zhang, H., Prahlad, J., Mahoney, J. P., Kirby, K. A., Sarafianos, S. G., & Wang, Z. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110119
Chitongo, R. (2020) · University of the Western Cape Electronic Theses and Dissertations Repository (University of the Western Cape)
HIV-1 Integrase Inhibitors Resistance: Update of the Current Literature
Maraolo, A. E. (2017) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-017-0113-0
Mesenteric Lymphatic Targeting of Antiretroviral agents for Improved Treatment of HIV/AIDS
Chu, Y. (2023) · Nottingham ePrints (University of Nottingham)
From bedside to bench and back : future options for antiretroviral drugs in non-B HIV-1 subtypes
Njenda, D. T. (2020) · Figshare
Santos, C. A. Q., & Quito, M. J. R. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0114
Santos, C. A. Q., & Quito, M. J. R. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0114
Cossu, M. V., Moschese, D., Matone, M., Oreni, L. M., Carrozzo, G., Poloni, A., Pozza, G., Albini, L., Forcina, G., Gervasoni, C., et al. (2026) · Infectious Diseases and Therapy · doi:10.1007/s40121-026-01408-2
Buzón, L., Bernal, E., Montes, M. L., Gisbert, L. M., & Troya, J. (2026) · AIDS · doi:10.1097/qad.0000000000004581
Evaluating the combination of bictegravir and lenacapavir as a single tablet option for HIV
Jayaweera, D. T., Albukhari, M., Pabón, F., Jayasekera, A., Dong, C., Galo, G., & Chaudhuri, S. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2708165
Bictegravir/Lenacapavir: A 2-Drug Regimen for the Treatment of HIV-1 Infection
Chahine, E. B., Faragon, J. J., Patel, N., & Sherman, E. M. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261496876
Ontwikkeling en SAR verkenning van nieuwe doravirine- en catechol-afgeleide hybride NNRTIs
Goffin, E. (2025) · Lirias (KU Leuven)
Farmacogenética aplicada aos inibidores da integrase na terapêutica antirretroviral
Couto, B. D. S. (2020) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Metadata
- Authors
- Tsiang, M., Jones, G. S., Goldsmith, J., Mulato, A., Hansen, D., Kan, E., Tsai, L., Bam, R. A., Stepan, G., Stray, K. M., Niedziela-Majka, A., Yant, S. R., Yu, H., Kukolj, G., Cihlar, T., Lazerwith, S. E., White, K. L., & Jin, H.
- Affiliations
- Gilead Sciences (United States) (US)
- Gilead Sciences, Foster City, California, USA
- Corresponding author
- White, Kirsten L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2016-12
- Volume
- 60
- Issue
- 12
- Pages
- 7086-7097
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5118987
- OpenAlex
- W2523305619
- Cited by
- 290
- References
- 50
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 24 · 2023: 25 · 2022: 24 · 2021: 40 · 2020: 37 · 2019: 38 · 2018: 36 · 2017: 18 · 2016: 2
- FWCI
- 28.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- bictegravir, antiviral activity, drug resistance, integrase inhibitors, dolutegravir, raltegravir, elvitegravir, cross-resistance, viral breakthrough, tenofovir alafenamide, emtricitabine, darunavir, drug selectivity
- MeSH terms
- Raltegravir Potassium, Dolutegravir, Amides, Cell Line, Drug Synergism, Heterocyclic Compounds, 3-Ring, Heterocyclic Compounds, 4 or More Rings, Humans, Mutation, Oxazines, Piperazines, Pyridones, HIV-1, Anti-HIV Agents, HIV Integrase, HIV Integrase Inhibitors, Drug Resistance, Viral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.